Replies to post #162494 on Biotech Values

[DewDiligence]

BRLI says it will compete with MYGN; it must have had this PR ready to go pending the Supreme Court ruling:

http://finance.yahoo.com/news/genedx-launch-comprehensive-breast-cancer-161400382.html

GeneDx, one of the world's foremost genetic testing laboratories and a subsidiary of Bio-Reference Laboratories, Inc. (BRLI) announced today its intention to launch a suite of comprehensive genetic tests for inherited cancers including BRCA1 and BRCA2 genes…

[biotech jim]

I agree that was a pretty good summary of the SCOTUS ruling, but I had to laugh when I read the following statement from Justice Thomas:

“but the lab technician unquestionably creates something new when cDNA is made.”

Except of course for those doggone single exon coding region gene segments that occur in some genes, or bioacitve peptides encoded within single genomic exons, of which there are many.

The concept of cDNA patentability versus the gene sequence non-patentability is silly on one level to those that have cloned both genomic and complementary DNAs. The ideas and methods are similar, as well as many anticipated uses, but essentially only a reverse transcription step makes all the difference.

[north40000]

I never know whether the summary is good until I have read the original opinion. I think I have a link for original; I will post it unless someone beats me to it.